Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04963946
Other study ID # FILOCLL14 - STAIR
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date October 18, 2021
Est. completion date August 1, 2028

Study information

Verified date June 2024
Source French Innovative Leukemia Organisation
Contact Marie POINSIGNON-BLANCARD
Phone 0467333190
Email m.poinsignon-blancard@filo-leucemie.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The irreversible Bruton's Tyrosine Kinase (BTK) inhibitor acalabrutinib (ACA) has potent clinical activity as a single agent in patients with treatment naive and Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). However, a growing body of concerns is raising regarding the unlimited administration of targeted therapy as BTKi. First, long-term treatments expose the patients to increased risk of specific adverse events (infections, bleeding events or cardiovascular problems). Second, continuous administration might also increase the risk of clonal evolution and therapeutic resistance resulting from genetic alterations such as BTK or PLCG2 mutations. Discontinuation of therapy after a fixed period is expected to prevent these events. Rapid and deep responses yielded by ACA in elderly patients pave the way of investigating a limited 18-months period schedule. This study aims to investigate the 1-year PFS upon ACA discontinuation and efficacy of restarting ACA upon symptomatic relapse.


Description:

This multicenter, non comparative, randomized phase II trial aims at evaluating the impact of a stopping ACA strategy on PFS of CLL patients >70 years or with coexisting comorbidities. Patients will receive continuous Acalabrutinib (ACA) at 100 mg bid for 18 months. Dose adaptations will be made according to labels. In case of first occurrence of grade ≥3 non-hematological toxicity, febrile grade ≥3 neutropenia or grade ≥4 hematological toxicity treatment must be stopped until recovering grade 1 or baseline state. - 1st and second occurrence : restart at 100 mg twice daily - 3rd occurrence : restart at 100 mg once daily - 4th occurrence : discontinue acalabrutinib At month 19 day 1, patients will be randomized (1:2) in two arms: - Arm 1 = Control arm (acalabrutinib) continuing acalabrutinib until disease progression or unacceptable toxicity or - Arm 2 = Experimental arm (watch and monitor) without ACA (see trial design). Upon progression in the experimental arm, all patients will be re-treated with ACA at the last received dose after central reviewing of treatment criteria. Upon progression in the control arm, patients will receive next line therapy at the discretion of their physicians and according to iwCLL 2018 criteria. Patients will be monitored every three months until M31 then every 6 months until M60 or progression for both response and toxicity according to CTCAE v.5. Minimal/Measurable Residual Disease (MRD) assessment will be done at month 19 day 1 in the peripheral blood. CT-scan will be performed at baseline, then at month 19 day 1 and every 6 months within the year after randomization.


Recruitment information / eligibility

Status Recruiting
Enrollment 160
Est. completion date August 1, 2028
Est. primary completion date January 31, 2026
Accepts healthy volunteers No
Gender All
Age group 70 Years and older
Eligibility Inclusion Criteria: - Age > 70 years or older - Eastern Cooperative Oncology Group (ECOG) performance status < 2 - Previously untreated CLL or Small Lymphocytic Lymphoma (SLL) - CLL or SLL requiring treatment according to the iwCLL 2018 criteria2 - Total Cumulative Illness Rating Scale (CIRS) score > 6 or 30 < CrCl < 69 mL/min - Both patients with or without TP53 disruption 17p deletion and/or TP53 mutations) can be included - Patients can be included whatever their IGHV mutational status - Patients with therapy-controlled cardiovascular comorbidities and/or anticoagulation (novel oral anticoagulant alone, aspirin alone, heparin alone) can be included (patients treated by vitamin K antagonist or dual anti-platelet therapy cannot be included) - Life expectancy > 6 months - Adequate hematology values: absolute neutrophil count = 0.75 x 109/L, platelet count = 50 x 109/L. - Adequate liver function as indicated by a total bilirubin <1.5, aspartate transaminase and alanine transaminase =3 the institutional upper limits of normal values, unless directly attributable to CLL - Signed (or their legally-acceptable representatives must sign) an informed consent document indicating that they understand the purpose of and procedures required for the study, including specify biology analysis, and are willing to participate in the study. Exclusion Criteria: - Known HIV seropositivity - Evidence of other clinically significant uncontrolled condition(s) including, but not limited to: - Uncontrolled and/or active systemic infection (viral, bacterial or fungal) - Known history of human immunodeficiency virus, serologic status reflecting active hepatitis B virus or hepatitis C virus infection, any uncontrolled active systemic infection along with subjects who are on ongoing anti-infective treatment and subjects who have received vaccination with a live attenuated vaccine within 4 weeks before the first dose of study treatment 1. Subjects who are hepatitis B core antibody (anti-HBc) positive and who are hepatitis B surface antibody (anti-HBs) negative will need to have a negative hepatitis B virus Polymerase Chain Reaction (PCR) result before enrollment. Those who are hepatitis B surface antigen (HBsAg) positive or hepatitis B virus PCR positive will be excluded. 2. Subjects who are hepatitis C virus antibody positive will need to have a negative hepatitis C virus PCR result before enrollment. Those who are hepatitis C virus PCR positive will be excluded - Active and uncontrolled autoimmune cytopenia, including autoimmune hemolytic anemia (AIHA) (isolated positive Direct Antiglobulin Testing (DAT) is not an exclusion criteria) and idiopathic thrombocytopenic purpura (ITP). - Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura. - Patients treated by vitamin K antagonist or dual anti-platelet therapy - History of bleeding diathesis (e.g. hemophilia or von Willebrand disease) - History of confirmed progressive multifocal leukoencephalopathy (PML). - Concurrent severe diseases which exclude the administration of therapy : - heart insufficiency New York Heart Association (NYHA) grade III/IV, Left Ventricular Ejection Fraction (LEVF) < 50% and or Recirculation Fraction (RF) < 30%, myocardial infarction within the past 6 months prior to study - Significant cardiovascular disease such as symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional (Subjects with controlled, asymptomatic atrial fibrillation are allowed to enroll on study) - severe chronic obstructive lung disease with hypoxemia - history of stroke or intra-cranial hemorrhage within the last 6 months - severe diabetes mellitus - uncontrolled hypertension - impaired renal function with creatinine clearance < 30 ml/min according the formula of Cockcroft and Gault - Patient who requires treatment with proton-pump inhibitors (e.g., omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole). Subjects receiving proton-pump inhibitors who switch to H2-receptor antagonists or antacids are eligible for enrollment in this study. - Disease significantly affecting gastrointestinal function (malabsorption syndrome, stomach or small bowel resection) - Evidence for Richter syndrome - Treatment with any of the following within 7 days prior to the first dose of study drug: steroid therapy for anti-neoplastic intent. - A significant history of renal, neurologic, psychiatric, endocrine, metabolic, immunologic, cardiovascular, or hepatic disease that, in the opinion of the investigator, would adversely affect the patient's participation in this study or interpretation of study outcomes - Major surgery within 30 days prior to the first dose of study treatment. - History of prior other malignancy that could affect compliance with the protocol or interpretation of results, with the exception of the following: - curatively treated basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix at any time prior to study. - other cancers not specified above that have been curatively treated by surgery and/or radiation therapy from which patient is disease-free for = 5 years without further treatment - Adult under law-control - Fertile male patients who cannot or do not wish to use an effective method of contraception, during and for 12 months after the final treatment used for the purposes of the study - No affiliation to social security

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Stop ACA
discontinuation of acalabrutinib after 18 months in treatment-naïve CLL patients
ACA Continuation
continuation of acalabrutinib at the same dose

Locations

Country Name City State
France Chu Angers Angers
France ARGENTEUIL - Centre hospitalier Victor Dupouy Argenteuil
France Ch Avignon Avignon
France Ch Cote Basque Bayonne
France BOBIGNY - Hôpital Avicenne Bobigny
France Hôpital Privé Sévigné Cesson-Sévigné
France CHU Estaing - Hématologie Clinique Adulte Clermont-Ferrand
France Corbeil-Essonnes - Corbeil-Essonnes
France CHU Grenoble - Hématologie Grenoble
France Centre Hospitalier du Mans Le Mans
France Hôpital Saint Vincent de Paul Lille
France Centre Léon Bérard - Hématologie Lyon
France Institut Paoli-Calmettes - Hématologie Clinique Marseille
France Centre Hospitalier Regional Metz Thionville Metz
France Hôpital Saint-Eloi - Hématologie Clinique Montpellier
France Hopital E.Muller Mulhouse
France CHR ORLEANS - Hématologie Orléans
France Hopital Pitie Salpetriere Service Hematologie Clinique - Pavillon de L'Enfant Et Adolescent Paris
France CENTRE HOSPITALIER SAINTJEAN - Hématologie Clinique Perpignan
France Bordeaux Pessac Pessac
France Centre Hospitalier Lyon Sud Pierre-Bénite
France Hôpital de la Milétrie - Hématologie et Thérapie Cellulaire Poitiers
France CERGY-PONTOISE - Centre Hospitalier René Dubos Pontoise
France Chu Reims Reims
France CHU Pontchaillou - Hématologie Clinique BMT-HC Rennes
France Centre Henri Becquerel - Service Hématologie Clinique Rouen
France Institut de Cancérologie Lucien Neuwirth Saint-Priest-en-Jarez
France IUCT ONCOPOLE - Hématologie Toulouse
France Hôpital Bretonneau - Hématologie et Thérapie Cellulaire Tours
France CHU Nancy Brabois Vandœuvre-lès-Nancy
France Vannes - Chba Vannes
France VERSAILLES - Hôpital André Mignot Versailles

Sponsors (1)

Lead Sponsor Collaborator
French Innovative Leukemia Organisation

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-free survival (PFS) at one year after acalabrutinib interruption Time from randomization (M19 : discontinuation of acalabrutinib after of 18 months treatment) to progression (needing therapy or not) or death from any cause until 12 months after acalabrutinib interruption
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02553447 - Cholecalciferol in Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D Deficiency N/A
Completed NCT03041636 - Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Phase 2
Active, not recruiting NCT04075292 - Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia Phase 3